Core Viewpoint - Samsung Medical is a leading provider in the energy metering and medical services sector, with significant technological strength in power grid equipment, and has shown strong revenue and profit performance in the industry [1][2]. Group 1: Business Performance - In Q3 2025, Samsung Medical achieved a revenue of 11.08 billion, ranking second among 26 companies in the industry, with the top company, Chint Electric, reporting a revenue of 46.396 billion [2]. - The company's net profit for the same period was 1.507 billion, also placing it second in the industry, while Chint Electric's net profit was 5.656 billion [2]. Group 2: Financial Ratios - As of Q3 2025, Samsung Medical's debt-to-asset ratio was 47.57%, an increase from 44.26% in the previous year and above the industry average of 40.49% [3]. - The company's gross profit margin for Q3 2025 was 28.46%, down from 36.21% year-on-year but still higher than the industry average of 23.98% [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 15.72% to 33,500, while the average number of circulating A-shares held per shareholder decreased by 13.94% to 41,900 [5]. - The fourth largest circulating shareholder is Hong Kong Central Clearing Limited, holding 51.056 million shares, an increase of 3.0756 million shares from the previous period [5]. Group 4: Order Backlog and Market Outlook - As of Q3 2025, the total order backlog for Samsung Medical reached 17.914 billion, a year-on-year increase of 14.69%, with overseas distribution orders at 2.169 billion, up 125.45% [5][6]. - The company is expected to see a recovery in its medical business, with a projected increase in the average price of domestic electric meters by 20-30% [6].